CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
the type of item being carried. For example, a kettle could fit into the category 'household goods'. how large the shipment is, in terms of both item size and quantity. how long the item for delivery will be in transit. Shipments are typically categorized as household goods, express, parcel, and freight shipments:
=== Barrier properties === In semi-crystalline polymers, the crystalline regions are considered to be gas impermeable. Due to relatively high crystallinity, in combination with the ability of the nanofibers to form a dense network held together by strong inter-fibrillar bonds (high cohesive energy density), it has been suggested that nanocellulose might act as a barrier material. Although the number of reported oxygen permeability values are limited, reports attribute high oxygen barrier properties to nanocellulose films. One study reported an oxygen permeability of 0.0006 (cm3 μm)/(m2 day kPa) for a ca. 5 μm thin nanocellulose film at 23 °C and 0% RH. In a related study, a more than 700-fold decrease in oxygen permeability of a polylactide (PLA) film when a nanocellulose layer was added to the PLA surface was reported. The influence of nanocellulose film density and porosity on film oxygen permeability has been explored. Some authors have reported significant porosity in nanocellulose films, which seems to be in contradiction with high oxygen barrier properties, whereas Aulin et al. measured a nanocellulose film density close to density of crystalline cellulose (cellulose Iß crystal structure, 1.63 g/cm3) indicating a very dense film with a porosity close to zero. Changing the surface functionality of the cellulose nanoparticle can also affect the permeability of nanocellulose films. Films constituted of negatively charged CNCs could effectively reduce permeation of negatively charged ions, while leaving neutral ions virtually unaffected.
=== EC 2.7.4: Phosphotransferases with a phosphate group as acceptor === EC 2.7.4.1: ATP-polyphosphate phosphotransferase EC 2.7.4.2: phosphomevalonate kinase EC 2.7.4.3: adenylate kinase EC 2.7.4.4: nucleoside-phosphate kinase EC 2.7.4.5: deleted, now included with EC 2.7.4.14 cytidylate kinase EC 2.7.4.6: nucleoside-diphosphate kinase EC 2.7.4.7: phosphomethylpyrimidine kinase EC 2.7.4.8: guanylate kinase EC 2.7.4.9: dTMP kinase EC 2.7.4.10: nucleoside-triphosphate—adenylate kinase EC 2.7.4.11: (deoxy)adenylate kinase EC 2.7.4.12: T2-induced deoxynucleotide kinase EC 2.7.4.13: (deoxy)nucleoside-phosphate kinase EC 2.7.4.14: cytidylate kinase EC 2.7.4.15: thiamine-diphosphate kinase EC 2.7.4.16: thiamine-phosphate kinase EC 2.7.4.17: 3-phosphoglyceroyl-phosphate—polyphosphate phosphotransferase EC 2.7.4.18: farnesyl-diphosphate kinase EC 2.7.4.19: 5-methyldeoxycytidine-5′-phosphate kinase EC 2.7.4.20: dolichyl-diphosphate—polyphosphate phosphotransferase EC 2.7.4.21: inositol-hexakisphosphate kinase EC 2.7.4.22: UMP kinase EC 2.7.4.23: ribose 1,5-bisphosphate phosphokinase EC 2.7.4.24: diphosphoinositol-pentakisphosphate kinase EC 2.7.4.25: (d)CMP kinase EC 2.7.4.26: isopentenyl phosphate kinase EC 2.7.4.27: [pyruvate, phosphate dikinase]-phosphate phosphotransferase EC 2.7.4.28: [pyruvate, water dikinase]-phosphate phosphotransferase EC 2.7.4.29: Kdo2-lipid A phosphotransferase EC 2.7.4.30: Now EC 2.7.8.43, lipid A phosphoethanolamine transferase EC 2.7.4.31: [5-(aminomethyl)furan-3-yl]methyl phosphate kinase EC 2.7.4.32: farnesyl phosphate kinase EC 2.7.4.33: AMP-polyphosphate phosphotransferase EC 2.7.4.34: GDP-polyphosphate phosphotransferase
High-Throughput Protein Laboratory for protein engineering Protein Purification Facilities for small- and large-scale protein production Macromolecular Crystallization & Crystallography Laboratories for solving crystal structures of biological molecules On-site X-ray facility Access to high energy synchrotron radiation at Argonne National Laboratory through the Life Science Collaborative Access Team (LS-CAT)
With the development of high-efficiency and high-power LEDs, it has become possible to use LEDs in lighting and illumination. To encourage the shift to LED lamps and other high-efficiency lighting, in 2008 the US Department of Energy created the L Prize competition. The Philips Lighting North America LED bulb won the first competition on August 3, 2011, after successfully completing 18 months of intensive field, lab, and product testing. Efficient lighting is needed for sustainable architecture. As of 2011, some LED bulbs provide up to 150 lm/W and even inexpensive low-end models typically exceed 50 lm/W, so that a 6-watt LED could achieve the same results as a standard 40-watt incandescent bulb. The lower heat output of LEDs also reduces demand on air conditioning systems. Worldwide, LEDs are rapidly adopted to displace less effective sources such as incandescent lamps and CFLs and reduce electrical energy consumption and its associated emissions. Solar powered LEDs are used as street lights and in architectural lighting. The mechanical robustness and long lifetime are used in automotive lighting on cars, motorcycles, and bicycle lights. LED street lights are employed on poles and in parking garages. In 2007, the Italian village of Torraca was the first place to convert its street lighting to LEDs. Cabin lighting on recent Airbus and Boeing jetliners uses LED lighting. LEDs are also being used in airport and heliport lighting.
Sources: en.wikipedia.org
== Function == Members of the ADAM family are cell surface proteins with a unique structure, possessing both potential adhesion and protease domains. Sheddase, a generic name for the ADAM metallopeptidase, functions primarily to cleave membrane proteins at the cellular surface. Once cleaved, the sheddases release soluble ectodomains with an altered location and function. Although a single sheddase may "shed" a variety of substances, multiple sheddases can cleave the same substrate resulting in different consequences. This gene encodes an ADAM family member that cleaves many proteins including TNF-alpha and E-cadherin. ADAM10 (EC#: 3.4.24.81) is a sheddase, and has a broad specificity for peptide hydrolysis reactions. ADAM10 cleaves ephrin, within the ephrin/eph complex, formed between two cell surfaces. When ephrin is freed from the opposing cell, the entire ephrin/eph complex is endocytosed. This shedding in trans had not been previously shown, but may well be involved in other shedding events. In neurons, ADAM10 is the most important enzyme, with α-secretase activity for proteolytic processing of the amyloid precursor protein. ADAM10, along with ADAM17, cleaves the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), to produce soluble TREM2 (sTREM2), which has been proposed as a CSF and sera biomarker of neurodegeneration. ADAM10 belongs to subfamily A, the most ancestral subfamily of ADAM proteins, which is shared by all major groups of animals, choanoflagellates, fungi, and green algae from the class Mamiellophyceae.
To do this, known controls are tested consecutively with unknown samples. By comparing the readouts of the controls with their known profiles the instrument can be confirmed to have been working properly at the time the unknowns were tested. Standards are also used to determine the instrument's limit of detection and limit of quantification for various common substances. Calculated quantities must be above the limit of detection to be confirmed as present and above the limit of quantification to be quantified. If the value is below the limit the value is not considered reliable.
The Christian New Testament notes that some people thought that Jesus was, in some sense, Elijah, but it also makes clear that John the Baptist is "the Elijah" who was promised to come in Malachi 3:1; 4:5. According to accounts in all three of the Synoptic Gospels, Elijah appeared with Moses during the Transfiguration of Jesus. In Western Christianity, Elijah is commemorated as a saint with a feast day on 20 July by the Roman Catholic Church and the Lutheran Church–Missouri Synod. Catholics believe that he was unmarried and celibate. In the Eastern Orthodox Church and those Eastern Catholic Churches which follow the Byzantine Rite, he is commemorated on the same date (in the 21st century, Julian Calendar 20 July corresponds to Gregorian Calendar 2 August). He is greatly revered among the Orthodox as a model of the contemplative life. He is also commemorated on the Orthodox liturgical calendar on the Sunday of the Holy Fathers (the Sunday before the Nativity of the Lord). John the Baptist is also known as John the Forerunner in Christianity, John the Immerser in some Baptist Christian traditions, He is considered to be a prophet of God by all of these faiths, and is honoured as a saint in many Christian denominations. According to the New Testament, John anticipated a messianic figure greater than himself, and the Gospels portray John as the precursor or forerunner of Jesus, since John announces Jesus' coming and prepares the people for Jesus' ministry.
==== "FDA-Cleared" vs "FDA-Approved" ==== Clearance requests are required for medical devices that prove they are "substantially equivalent" to the predicate devices already on the market. Approved requests are for items that are new or substantially different and need to demonstrate "safety and efficacy", for example they may be inspected for safety in case of new toxic hazards. Both aspects need to be proved or provided by the submitter to ensure proper procedures are followed.
Sources: en.wikipedia.org
=== High blood pressure === Valsartan and hydrochlorothiazide are both medications indicated as initial therapy for high blood pressure. When high blood pressure is not effectively controlled on a single medication they can be used in a combination.
Following Charles Darwin's 1859 On the Origin of Species, Fuhlrott and Schaaffhausen argued that Neanderthal 1 represents a primitive lower human form, aligning more closely with non-human apes as well as Negroids, Eskimos, and Aboriginal Australians (which were variably classified as separate species or subspecies of human at the time). The binomial name Homo neanderthalensis was first proposed by William King in a paper read to the 33rd British Science Association in 1863, formally recognising it as distinct from modern humans. However, in 1864 he recommended that Neanderthals and modern humans be classified in different genera as he compared the Neanderthal braincase to that of a chimpanzee and argued that they were "incapable of moral and [theistic] conceptions". The uniqueness of Neanderthal Man met opposition namely from the pathologist Rudolf Virchow, who argued against defining new species based on only a single find. In 1872, Virchow erroneously interpreted Neanderthal characteristics as evidence of senility, disease, and malformation instead of archaicness, which stalled Neanderthal research until the end of the century. By the early 20th century, numerous other Neanderthal discoveries were made, establishing H. neanderthalensis as a legitimate species. At first, many palaeontologists considered Neanderthals to be an intermediary phase between modern humans and more apelike ancestors, as suggested by German anatomist Gustav Albert Schwalbe.
Despite the health risks in certain cases, the nut-like kernels of the seeds are esteemed in Asia and are a traditional ingredient in Chinese food. Ginkgo nuts are used in congee, and are often served at special occasions such as weddings and the Chinese New Year (as part of the vegetarian dish called Buddha's delight). Japanese cooks add ginkgo seeds (called ginnan) to dishes such as chawanmushi, and cooked seeds are often eaten along with other dishes. Grilled ginkgo nuts with salt are also a popular item at izakayas as a snack with beer and other Japanese food. In Korea, ginkgo nuts are stir-fried and eaten, or are used to garnish foods such as sinseonro.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.